HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
about
Challenges and opportunities for the implementation of virological testing in resource-limited settingsExtreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuranPre-exposure Prophylaxis for HIV Prevention: Why, What, Who and HowAntiretroviral prophylaxis for HIV prevention in heterosexual men and womenHIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingIncrease of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native populationLow prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringHIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backboneMolecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, RwandaEvolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectorsPrevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009)Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in SpainComparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian PatientsElimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison studyLow primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, RwandaPatterns of transmitted HIV drug resistance in Europe vary by risk groupProfile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelagoCharacteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, ChinaDecreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivityHIV-1 diversity, transmission dynamics and primary drug resistance in AngolaMinority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCRVirological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in UgandaPrevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance AssayModerate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National SurveySimultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assayMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsAn affordable HIV-1 drug resistance monitoring method for resource limited settingsPharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesAnalysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.Spatiotemporal dynamics of the HIV-1 subtype G epidemic in West and Central Africa.Misdiagnosis of HIV treatment failure based on clinical and immunological criteria in Eastern and Central KenyaDecreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe.Primary drug resistance in South Africa: data from 10 years of surveys.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsOligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.Surveillance of transmitted HIV drug resistance in antiretroviral-naive patients aged less than 25 years, in Bangkok, Thailand.
P2860
Q27026923-7DDA8B22-3013-4984-BDE1-C22BABE0F24FQ27677405-08624FBA-A17E-40EE-BBB0-04BB6B12F17EQ28080301-E6F6D1FF-DD40-4AFD-AA82-D0440605D5BCQ28270788-CE54EDFE-534E-49BE-A6C4-3B47B58413FCQ28271593-79592A50-9A73-4022-8195-BAEDB1AC0C6DQ28477624-6CA04824-B530-4504-9895-4B2051BFAF8CQ28481603-D02816D2-60BF-49FD-AAA6-1420203C1F9BQ28482138-0CA46EAA-B537-4E4F-8E5E-C62F3531C1ECQ28482189-A36EFDB2-4090-416E-B353-10A69EA2C433Q28482242-46D75D02-07F6-407F-8C0C-C1FB7A91F60FQ28484825-81A2E74C-7DFB-4351-B50A-9C0A97BED83DQ28486101-205F0247-15F5-4E79-BD85-4E996DA32E70Q28533216-FC969F4E-237E-4F16-8485-A33700FB144EQ28534376-B3B222B5-4D66-448F-B4BE-8C17A9B1BA8CQ28534568-FCCE51D5-4367-4A93-9822-B098ECBDF08AQ28535266-32EBD75B-00BC-407A-99D1-800BEB6C6089Q28537726-7307EDEA-08A8-4F0D-BF72-489A9FE1462DQ28538242-BCAD56F1-13D1-4DB8-819C-C80BFC15A76DQ28539927-E67C8D1F-316C-4B58-A986-6AFED048E2E2Q28540368-4D8F0C73-A438-4080-ACA9-CFAB35C69C02Q28542528-2D7C61F8-00D6-463B-A215-3DFAD4775812Q28543986-3685AF7C-95D9-4CEA-9C0F-616FAB4DA5F1Q28551745-A3050E6B-E3B1-4EAC-9F41-9ECA93C7DCA3Q28553024-DE3F3D3D-F203-4016-B058-E9B7ED411EBCQ28554729-0952B7D6-A924-4FB1-B63F-2F4FD81EFC00Q28660673-199CAEB5-B3B9-4602-BE31-9A2A3947B870Q28728304-668FAF88-B732-4C53-9823-E9B94D2835B1Q30486897-F3F20A4D-225B-4347-94D1-823D76655100Q31150044-F24778E8-AD45-4E15-A672-96BDAFF59894Q33597247-D73F92B4-6952-4741-AED5-05A9864B6D3AQ33668468-B30A6D6D-14F4-4DA9-A6BA-1D3BB500E749Q33740286-3E316105-24CD-470A-A4F7-BD04B625EEE2Q33759577-8E874500-12AB-4B95-A41A-892B5BAC057DQ33810988-C83D99D1-9072-4AF8-AD25-B0570E03AA19Q33820125-C4AFA75C-20AB-482C-9349-03A00F510A65Q33849840-26E592E9-7417-48B6-A8D8-C4AF141219C7Q34129300-5F6609AE-4B8B-490B-BD23-C7E8B1AF6AD0Q34280466-AE6DB910-1330-45D7-847C-7A7D8DFC1C76Q34339340-0258C478-5252-4A67-96D7-D865A7119C61Q34346783-D744C827-D952-434C-A685-1E6B22C37628
P2860
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HIV-1 drug resistance in antir ...... lticentre observational study.
@en
type
label
HIV-1 drug resistance in antir ...... lticentre observational study.
@en
prefLabel
HIV-1 drug resistance in antir ...... lticentre observational study.
@en
P2093
P921
P1476
HIV-1 drug resistance in antir ...... lticentre observational study.
@en
P2093
Akin Osibogun
Carole L Wallis
Cissy Kityo
Ferdinand W Wit
Francesca Conradie
Immaculate Nankya
Kim C E Sigaloff
Kishor Mandaliya
Margaret Siwale
Mariette E Botes
P304
P356
10.1016/S1473-3099(11)70149-9
P577
2011-07-27T00:00:00Z